We will discuss two platforms of haploidentical HSCT(haplo-HSCT): ex vivo T cell depletion and unmanipulated in vivo T-cell depletion. The former has evolved from positive selection of CD34+ cells to selection of CD34+ cells associated with alpha/beta T cell and CD19 B cell depletion. We will outline the outcome of these procedures in children and adults. More recently selective add back of Treg Tcon has also been developed and will be discussed. The second platform is unmanipulated haplo-HSCT: PTCy and ATG have been used alone or in combination to optimize prevention of GvHD. We will discuss the outcome in patients with hematologic malignancies as well as in patients with non-malignant disorders, such as aplastic anemia, hemoglobinopathies, and immune deficiencies.
Haploidentical HCT / Bacigalupo, A., Lankester, A., Ciceri, F., Bertaina, A.. - (2024), pp. 577-585. [10.1007/978-3-031-44080-9_65]
Haploidentical HCT
Ciceri F.;
2024-01-01
Abstract
We will discuss two platforms of haploidentical HSCT(haplo-HSCT): ex vivo T cell depletion and unmanipulated in vivo T-cell depletion. The former has evolved from positive selection of CD34+ cells to selection of CD34+ cells associated with alpha/beta T cell and CD19 B cell depletion. We will outline the outcome of these procedures in children and adults. More recently selective add back of Treg Tcon has also been developed and will be discussed. The second platform is unmanipulated haplo-HSCT: PTCy and ATG have been used alone or in combination to optimize prevention of GvHD. We will discuss the outcome in patients with hematologic malignancies as well as in patients with non-malignant disorders, such as aplastic anemia, hemoglobinopathies, and immune deficiencies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
